--- title: "Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7 | Sutter Health" description: "A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression" url: "https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7 # Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06767514). #### Locations - San Francisco - Sacramento - Palo Alto - Fremont - Sunnyvale #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival. ![Edmund W Tai, M.D., FACP](https://dyn.mktgcdn.com/p/wYUVzA2p9c43sVmazBXuZrEqT_9gDAEd_juzF2bvph0/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Edmund W Tai, M.D., FACP Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/edmund-w-tai-md-facp-1049681048) ## Sub-Investigators [Kim-Son Nguyen, M.D., MPA](https://www.sutterhealth.org/research/investigators/kim-son-nguyen-md-mpa-1049681024) , [Ari D Baron, M.D.](https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174) , [Natalia Colocci, M.D., Ph.D.](https://www.sutterhealth.org/research/investigators/natalia-colocci-md-phd-1049680997) , [Huy V Nguyen, M.D.](https://www.sutterhealth.org/research/investigators/huy-v-nguyen-md-2015846698) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Metastatic%201st%20Line%20Non-Small%20Cell%20Lung%20Cancer%20HARMONi-7%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Metastatic%201st%20Line%20Non-Small%20Cell%20Lung%20Cancer%20HARMONi-7%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Palo Alto](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Metastatic%201st%20Line%20Non-Small%20Cell%20Lung%20Cancer%20HARMONi-7%20in%20Palo%20Alto&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Fremont](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Metastatic%201st%20Line%20Non-Small%20Cell%20Lung%20Cancer%20HARMONi-7%20in%20Fremont&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Sunnyvale](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Metastatic%201st%20Line%20Non-Small%20Cell%20Lung%20Cancer%20HARMONi-7%20in%20Sunnyvale&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-early-stage-non-small-cell-lung-cancer-beamion-lung-3-2084403277) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer](https://www.sutterhealth.org/research/clinical-trials/adjuvant-monotherapy-vs-standard-of-care-early-stage-resectable-non-small-cell-lung-cancer-2082765455) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Coming Soon - Clinical trial ### [Adjuvant Non Small Lung Cancer TroFuse-019](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648) A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Non-Small Cell Lung Cancer A081801](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795) Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-c5851005-padl1nk-005-2064313501) PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965#medicalwebpage","name":"Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7","description":"A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression","url":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965#breadcrumblist"},"mentions":[{"@type":"Person","name":"Edmund W Tai, M.D., FACP","url":"https://www.sutterhealth.org/research/investigators/edmund-w-tai-md-facp-1049681048","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965#medicaltrial","name":"Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7","alternateName":"A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression","url":"https://www.sutterhealth.org/research/clinical-trials/metastatic-1st-line-non-small-cell-lung-cancer-harmoni-7-2015845965","description":"Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.","identifier":"NCT06767514","code":{"@type":"MedicalCode","codeValue":"NCT06767514","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06767514","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Lung Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"},{"@type":"AdministrativeArea","name":"Sacramento"},{"@type":"AdministrativeArea","name":"Palo Alto"},{"@type":"AdministrativeArea","name":"Fremont"},{"@type":"AdministrativeArea","name":"Sunnyvale"}]} ```